NasdaqGS - Delayed Quote USD
Arbutus Biopharma Corporation (ABUS)
3.3400
+0.1000
+(3.09%)
At close: 4:00:00 PM EDT
3.2306
-0.11
(-3.28%)
After hours: 4:08:18 PM EDT
Insider Purchases Last 6 Months
| Shares | Transactions | |
|---|---|---|
| Purchases | 193,700 | 3 |
| Sales | 52,864 | 3 |
| Net Shares Purchased (Sold) | 140,836 | 6 |
| Total Insider Shares Held | 41.93M | -- |
| % Net Shares Purchased (Sold) | 0.30% | -- |
Net Institutional Purchases Prior Quarter to Latest Quarter
| Shares | |
|---|---|
| Net Shares Purchased (Sold) | -- |
| % Change in Institutional Shares Held | -- |
Insider Transactions Reported - Last Two Years
| Insider | Transaction | Type | Value | Date |
|---|---|---|---|---|
| NAFTZGER J CHRISTOPHER General Counsel | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 14, 2025 |
| HASTINGS DAVID C Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 14, 2025 |
| SIMS KAREN Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 14, 2025 |
| NAFTZGER J CHRISTOPHER General Counsel | Sale at price 3.28 per share. | Direct | 37,206 | Feb 4, 2025 |
| HASTINGS DAVID C Chief Financial Officer | Sale at price 3.28 per share. | Direct | 72,827 | Feb 4, 2025 |
| SIMS KAREN Officer | Sale at price 3.28 per share. | Direct | 63,519 | Feb 4, 2025 |
| MANCHESTER KEITH S Director | Sale at price 3.69 per share. | Direct | 32,637 | Aug 14, 2024 |
| MANCHESTER KEITH S Director | Conversion of Exercise of derivative security at price 0.56 per share. | Direct | 30,752 | Aug 14, 2024 |
| SOFIA MICHAEL JOSEPH Officer | Sale at price 2.31 per share. | Direct | 23,083 | Feb 2, 2024 |
| HASTINGS DAVID C Chief Financial Officer | Sale at price 2.31 per share. | Direct | 22,184 | Feb 2, 2024 |
| MC ELHAUGH MICHAEL JOHN Chief Executive Officer | Sale at price 2.31 per share. | Direct | 23,504 | Feb 2, 2024 |
| SIMS KAREN Officer | Sale at price 2.31 per share. | Direct | 10,078 | Feb 2, 2024 |
| SOFIA MICHAEL JOSEPH Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 1, 2024 |
| NAFTZGER J CHRISTOPHER General Counsel | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 1, 2024 |
| HASTINGS DAVID C Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 1, 2024 |
| MC ELHAUGH MICHAEL JOHN Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 1, 2024 |
| SIMS KAREN Officer | Stock Award(Grant) at price 0.00 per share. | Direct | 0 | Feb 1, 2024 |
Related Tickers
ROIV Roivant Sciences Ltd.
11.00
+2.42%
ARWR Arrowhead Pharmaceuticals, Inc.
13.34
+2.54%
IMVT Immunovant, Inc.
15.07
+4.29%
FOLD Amicus Therapeutics, Inc.
7.20
+1.41%
MREO Mereo BioPharma Group plc
2.5400
-0.78%
CVAC CureVac N.V.
3.2600
+2.84%
RIGL Rigel Pharmaceuticals, Inc.
19.06
+4.96%
PRAX Praxis Precision Medicines, Inc.
36.00
-1.61%
SWTX SpringWorks Therapeutics, Inc.
44.93
+9.03%
CLDX Celldex Therapeutics, Inc.
19.58
+0.77%